Home Blog Page 84

Verifact Markets Unveils First Trading Platform to Find Truth in Disputed Facts

Think prediction markets, but instead of asking what will happen, Verifact Markets combines evidence analysis and market structure to settle what actually happened.

CHICAGO, Oct. 7, 2026 /PRNewswire/ — Verifact Markets launches the first trading platform built to resolve disputed facts. This is a new category of markets, focused on topics of public interest where people genuinely disagree about what is true.

“We’re living in the age of disputed facts. Making or amplifying a claim has never been easier. Resolving one has never been harder,” said Rodrigo Aquino, CEO of Verifact Markets. “Our company exists to change that.”

Verifact Markets is headquartered in Chicago and backed by Positron Capital Management, a multibillion-dollar family office with active investments at the intersection of technology and finance, including prediction markets.

How it works

Users can review arguments and trade True or False contracts. The experience is similar to prediction markets, but the resolution is based on evidence, which users may contribute to.

Verifact Markets uses a patent-pending framework to evaluate evidence at scale along with market structure to resolve markets.

Verifact analyzes data from many sources, including evidence discovered by our systems and evidence submitted by users, and assesses how strongly the overall body of information supports each side.

A market resolves only when Verifact reaches a high level of confidence.

Winning positions pay $1, losing positions pay $0. Same as prediction markets.

When markets remain inconclusive, users still receive their payout. If trading activity fades and no new evidence emerges after a period of time, Verifact may expire the market. Positions are then settled using a trusted expiration price calculated from recent qualifying trades.

Examples of Verifact Markets

Markets offer a mix of long-contested claims and current ones, spanning political, business and cultural topics.

  • “COVID-19 originated in a laboratory in the Wuhan Institute of Virology.”
  • “Meta overstated the privacy of WhatsApp in its ‘Not Even WhatsApp’ ad campaign”
  • “The Pentagon fired Stars and Stripes journalists due to USS Abraham Lincoln reporting.”

During its recent private beta, a market on whether the “LA Clippers used Kawhi Leonard’s endorsement deals to circumvent the NBA salary cap” resolved True.

Team

Verifact Markets is led by a team with decades of experience at the intersection of financial markets and technology, combining hands-on experience founding, operating, and investing in companies with deep expertise in building intelligence systems that process large amounts of information to separate signal from noise.

About Verifact Markets

Verifact Markets is the first trading platform built to find truth in disputed facts. Unlike prediction markets, which ask what will happen, Verifact Markets asks what actually happened. Users trade True or False contracts on contested topics of public interest. Market resolution is based on evidence, which users may contribute to.

Verifact is available to eligible users in several jurisdictions outside the United States, while pursuing the necessary regulatory pathway for a U.S. launch.

Verifact Markets – Trade on disputed facts. 

See the evidence. Take a position. Join the search for truth.

For more information, visit verifact.markets or reach out to press@verifactm.com

Cambridge Heartwear Awarded £184 Million NHS Tender for World’s First Medical-Grade, Wirelessly Charged, Reusable ECG Wearable

CAMBRIDGE, England, Oct. 7, 2026 /PRNewswire/ — Cambridge Heartwear® Limited (www.camheartwear.com) has secured a landmark £184 million tender with the National Health Service (NHS) of the UK for HeartSense®, the world’s first medical-grade, multi-channel, portable, wirelessly charged ECG wearable straight to one’s mobile phone, representing a significant advancement in global Medical technology, AI application and cardiovascular diagnostics. 

Cambridge Heartwear Awarded £184 Million NHS Tender for World's First Medical-Grade, Wirelessly Charged, Reusable ECG Wearable
Cambridge Heartwear Awarded £184 Million NHS Tender for World’s First Medical-Grade, Wirelessly Charged, Reusable ECG Wearable

The agreement with the UK National Health Service Supply chain enables the deployment of advanced cardiac monitoring technology across primary and secondary care and civil service departments, empowering patients to diagnose heart rhythm problems whenever and wherever they are to prevent heart failure and strokes earlier, reduce waiting times and support a more preventative approach to Heart Disease, which can take place in the comfort of their own homes. 

HeartSense® is the world’s first wearable to combine diagnostic-grade multi-channel ECG monitoring, adaptive artificial intelligence and wireless charging in a single device. Manufactured to bridge the gap in women’s cardiovascular care with its ergonomic design, the technology gives healthcare professionals and patients access to continuous, real-time ECG data on a mobile phone. giving you back the control of your health at every stage. 

Engineered in Cambridge and manufactured in Britain, HeartSense® has been developed to help identify cardiovascular disease and stroke risk before conditions become acute. Its proprietary engineering and AI technology with (86 patents ) support earlier intervention, enabling clinicians to make more informed decisions and improve patient outcomes. 

The system is UKCA approved and ISO 13845 certified, with FDA 510(k) applications currently in progress. 

“We did not have a UK ECG manufacturer and reporter until now,” said Professor Rameen Shakur, Founder of Cambridge Heartwear. “HeartSense® is the world’s first medical-grade, AI-powered, multi-channel ECG wearable and demonstrates what can be achieved when clinicians, engineers and AI specialists work together. We want to help move healthcare towards earlier diagnosis, better prevention and improved outcomes for patients across the NHS.” 

The partnership with the NHS Supply Chain allows Integrated Care Boards to deploy HeartSense® at scale, supporting the delivery of diagnostic-quality heart monitoring beyond hospital environments. The initiative is intended to reduce pressure on secondary care services while improving access to high-quality cardiac diagnostics in community settings. 

Founded by Professor Rameen Shakur, Cambridge Heartwear is a medical technology company based at Cambridge Science Park coming out of the University of Cambridge dedicated to making heart health monitoring simple, accessible and accurate. Combining medical research, engineering excellence and artificial intelligence, the company develops advanced wearable technologies that empower patients and healthcare professionals with diagnostic-quality cardiovascular insights anytime, anywhere. HeartSense® helps detect heart conditions earlier, enabling more informed clinical decision-making and better patient care.

Contact: info@camheartwear.com

Cambridge Heartwear Awarded £184 Million NHS Tender for World’s First Medical-Grade, Wirelessly Charged, Reusable ECG Wearable

CAMBRIDGE, England, Oct. 7, 2026 /PRNewswire/ — Cambridge Heartwear® Limited (www.camheartwear.com) has secured a landmark £184 million tender with the National Health Service (NHS) of the UK for HeartSense®, the world’s first medical-grade, multi-channel, portable, wirelessly charged ECG wearable straight to one’s mobile phone, representing a significant advancement in global Medical technology, AI application and cardiovascular diagnostics. 

Cambridge Heartwear Awarded £184 Million NHS Tender for World's First Medical-Grade, Wirelessly Charged, Reusable ECG Wearable
Cambridge Heartwear Awarded £184 Million NHS Tender for World’s First Medical-Grade, Wirelessly Charged, Reusable ECG Wearable

The agreement with the UK National Health Service Supply chain enables the deployment of advanced cardiac monitoring technology across primary and secondary care and civil service departments, empowering patients to diagnose heart rhythm problems whenever and wherever they are to prevent heart failure and strokes earlier, reduce waiting times and support a more preventative approach to Heart Disease, which can take place in the comfort of their own homes. 

HeartSense® is the world’s first wearable to combine diagnostic-grade multi-channel ECG monitoring, adaptive artificial intelligence and wireless charging in a single device. Manufactured to bridge the gap in women’s cardiovascular care with its ergonomic design, the technology gives healthcare professionals and patients access to continuous, real-time ECG data on a mobile phone. giving you back the control of your health at every stage. 

Engineered in Cambridge and manufactured in Britain, HeartSense® has been developed to help identify cardiovascular disease and stroke risk before conditions become acute. Its proprietary engineering and AI technology with (86 patents ) support earlier intervention, enabling clinicians to make more informed decisions and improve patient outcomes. 

The system is UKCA approved and ISO 13845 certified, with FDA 510(k) applications currently in progress. 

“We did not have a UK ECG manufacturer and reporter until now,” said Professor Rameen Shakur, Founder of Cambridge Heartwear. “HeartSense® is the world’s first medical-grade, AI-powered, multi-channel ECG wearable and demonstrates what can be achieved when clinicians, engineers and AI specialists work together. We want to help move healthcare towards earlier diagnosis, better prevention and improved outcomes for patients across the NHS.” 

The partnership with the NHS Supply Chain allows Integrated Care Boards to deploy HeartSense® at scale, supporting the delivery of diagnostic-quality heart monitoring beyond hospital environments. The initiative is intended to reduce pressure on secondary care services while improving access to high-quality cardiac diagnostics in community settings. 

Founded by Professor Rameen Shakur, Cambridge Heartwear is a medical technology company based at Cambridge Science Park coming out of the University of Cambridge dedicated to making heart health monitoring simple, accessible and accurate. Combining medical research, engineering excellence and artificial intelligence, the company develops advanced wearable technologies that empower patients and healthcare professionals with diagnostic-quality cardiovascular insights anytime, anywhere. HeartSense® helps detect heart conditions earlier, enabling more informed clinical decision-making and better patient care.

Contact: info@camheartwear.com

femtoAI Opens Developer Community to Build New AI Powered Products

Unlocks access to femtoAI’s full-stack AI silicon and compression platform that delivers 10X memory & power savings

SAN BRUNO, Calif., Oct. 7, 2026 /PRNewswire/ — femtoAI, a leading full-stack AI silicon and compression platform, today announced open access to its developer community after a successful beta program. Developers now will have access to femtoAI’s full-stack compression AI platform including the femtoAI Sparse Processing Unit (SPU) chip evaluation kit, compressed models, compiler and Sparsity Studio™ that easily enable development of new AI powered products. femtoAI technology turns patented neural-network sparsity and advanced model compression into real savings, delivering a 10X lower power draw and 10X smaller memory footprint without sacrificing accuracy. Developers can now see what’s possible with femtoAI tools and systems at developer.femto.ai.

femtoAI developer community
femtoAI developer community

“We’ve been working behind the scenes in our developer community with dozens of enterprises as they create new products based on femtoAI’s unique full-stack AI silicon and compression platform. The time to open this experience to more enterprises and developers is now,” said Bill Hoppin, Chief Business Officer, femtoAI. “Customers such as Legato and Marshall gained a competitive advantage by easily developing and deploying using our developer tools and systems. By now opening up the experience for everyone, we can’t wait to see how developers across all industries innovate with the power of our full-stack AI compression platform.”

Key features of the femtoAI developer community include: 

  • SPU Evaluation Kit: Order your own kit to access the SPU chip
  • Self-service development: Access to the full suite of femtoAI tools, compilers and models
  • Model flexibility: Bring your own model, use one of femtoAI’s prebuilt models, or develop from scratch with easy-to-use tools and agent-friendly documentation readily available.
  • Sparsity Studio™: See actual power and memory savings unlocked by femtoAI sparsity with this measurement tool
  • Community Forum: Ongoing open discussion and Q&A with femtoAI experts and developers 

“At femtoAI, not only do we deliver first-class sparsity in both our hardware and software tooling and applications,” said Sangnam Choi, VP of Audio & Sensing at femtoAI, “but we also apply advanced model compression techniques that have allowed us to deliver open-source models such as OpenAI Whisper at 10X less memory, and develop custom solutions like local voice commands.  Our team continues to unearth and implement emerging techniques and methods, and in turn, we’re able to deliver with an even lower power and memory footprint. We’ll continue to push the possibilities on performance without sacrificing accuracy.”

femtoAI developer community enables faster time-to-market

The femtoAI developer platform has already been instrumental for work across femtoAI’s audio and sensing business with customers such as smart glasses disruptors Legato, and headphone and earbud icon Marshall and innovative companies like NewSound have leveraged femtoAI’s technology to build AI enhanced audio solutions with 10X less memory and 10X less power.

“Integrating advanced AI audio solutions on the femtoAI platform has been a tremendous success for us. The combination of easy-to-use tools, innovative capabilities, and amazing support helped us achieve a level of hearing performance for Legato Frames that was previously impossible in the form factor on a remarkable timeline,” Mehul Trivedi, CEO at Legato Hearing said. “We’ve loved working with the femtoAI team and are excited to continue delivering industry-leading products with them. It’s an extraordinarily valuable partnership for Legato, both now and as we grow.”

Join the Community

Meet the femtoAI team on Wednesday October 7 for an SF Tech Week developer happy hour at Barebottle Brewing Company’s beer garden located at Salesforce Park. You’ll enjoy drinks, light bites, and an exclusive walk-through of the developer community from femtoAI experts. RSVP today to join us.

To join our developer community and access the femtoAI platform, visit developer.femto.ai.

About femtoAI 

femtoAI is a leading full-stack AI silicon and compression platform that turns patented neural-network sparsity into real savings for enterprises. Headquartered in Silicon Valley, femtoAI was founded in 2018 by researchers from the Brains in Silicon Lab at Stanford University. femtoAI’s full-stack AI silicon and compression platform enables low-latency, 10X lower power draw and 10X smaller memory footprint for customers like Marshall, NewSound and Legato. From wearables and household appliances to smart glasses and robotics, femtoAI brings the power of AI to every device.

Sparsity Studio™
Sparsity Studio™

Cofounder.AI Names Former Google X Leader AJ Thomas Chief Operating Officer

Venture investor, operator and founder coach joins the AI-native startup to scale partnerships and operations, and brings Cofounder.AI to every Good Trouble Ventures portfolio founder

LOS ANGELES, Oct. 6, 2026 /PRNewswire/ — Cofounder.AI, the venture-backed, AI-native startup leveling the playing field for small business owners and entrepreneurs, today announced that AJ Thomas has joined as Chief Operating Officer. Thomas will lead Partnerships and oversee Finance, Legal and HR alongside CEO Clarence Wooten, her former colleague at Google X, Alphabet’s Moonshot Factory. At Google X, she served as Global Head of Talent & People Products. She is also cofounder of Troublemaker Ventures, home to the venture fund Good Trouble Ventures and the growth advisory firm The Troublemaker Lab.

The appointment brings Thomas’s work full circle. After years of investing in, coaching and championing founders, she will now help build technology that puts that same support in the hands of entrepreneurs everywhere.

“Most small business owners are building alone, without a cofounder, operating leverage or a board to lean on,” said Clarence Wooten, Founder and CEO of Cofounder.AI. “AJ has spent her career giving founders exactly that kind of support, at Google X, as an investor, and as an operator and leadership coach. She knows what it takes to build teams and companies that last, and she’s the right person to scale Cofounder.AI’s partnerships and operations.”

“I’ve sat on every side of the table: operator, investor and leadership coach. The pattern is the same everywhere. Talent is evenly distributed, but support is not,” said Thomas. “Cofounder.AI gives every entrepreneur the operating leverage that used to be reserved for founders with the right network. My job is to make sure humanity and technology get equal weight as we build it, so we can deliver on our mission for the entrepreneurs and small business owners who are the heartbeat of our economy.”

Capital, culture and community

Thomas brings more than 15 years of experience across venture capital, talent and company building. Her work at Troublemaker Ventures, which backs founders and their teams with both capital and hands-on support, runs on three levers:

Capital. As General Partner of Good Trouble Ventures, she invests in founders who challenge the status quo.

Culture. As Managing Partner of The Troublemaker Lab, she coaches founders and enterprise teams on growth strategy, go-to-market, operational rigor and building cultures that hold up under pressure, including adopting AI in ways that sharpen teams rather than replace them.

Community. She connects founders, investors, operators and technologists across AI, emerging tech and venture capital, widening access to the rooms and resources that shape innovation.

At Cofounder.AI, Thomas’s early priorities include expanding university and ecosystem partnerships that bring the platform to student and early-stage founders. She is also a sought-after voice on how AI is reshaping funding, teams and communities; an executive coach and advisor to multiple startups; and a bestselling children’s book author.

Alliance with Good Trouble Ventures

Alongside the appointment, Cofounder.AI and Good Trouble Ventures are forming an alliance partnership. Every current and future Good Trouble Ventures portfolio founder will receive a free one-year Cofounder.AI license, giving them an AI cofounder for fundraising readiness, diligence and day-to-day operations from day one.

“Capital alone doesn’t build a company. Operating leverage does,” said Kat Steinmetz, Cofounder and General Partner of Good Trouble Ventures. “Putting Cofounder.AI in every founder’s hands means our support doesn’t stop when the meeting ends.”

About Cofounder.AI

Cofounder.AI is a venture-backed, AI-native startup leveling the playing field for small business owners and entrepreneurs. Founded by Clarence Wooten, a two-time exited founder and former Executive Entrepreneur in Residence at Google X, Cofounder.AI gives every entrepreneur an AI cofounder to help them plan, fund and run their business.

About Troublemaker Ventures

Troublemaker Ventures is a holding company that backs founders with both capital and hands-on support. It operates through two businesses: Good Trouble Ventures, an early-stage fund investing in category-creating founders, and The Troublemaker Lab, an advisory firm that coaches founders and enterprise teams on growth strategy, financial and operational rigor, and culture.

Media Contact
press@cofounder.ai • 310.400.2434

XtalPi Debuts Kodexia™, the World’s First Closed-Loop siRNA Platform Combining Generative AI with First-Principles Modeling

  • This unified platform integrates sequence design, chemical modification, experimental validation, extrahepatic delivery design, and intellectual property strategy into an integrated computational–experimental workflow, pioneering in vivo efficacy prediction models to accelerate drug development.
  • Validating this infrastructure, XtalPi announced the advancement of six proprietary preclinical programs targeting complex diseases, with the first one reaching NHP data in just 7 months; in utilizing optimized ligand-based delivery mechanisms, XtalPi is advancing RNA interference therapies beyond the liver.
  • Internal preclinical data benchmarking demonstrates a nearly threefold increase in molecular design efficiency compared to conventional workflows, alongside a first-round in vivo hit rate exceeding 50% across multiple target programs.

BOSTON and BEIJING, Oct. 6, 2026 /PRNewswire/ — XtalPi Holdings Limited (HKEX: 2228), an AI and robotics-driven drug and materials discovery company, today debuted Kodexia™, the industry’s first closed-loop small interfering RNA (siRNA) discovery platform combining generative AI, first-principles-driven biological modeling, and automated experimentation. Validating the rapid execution capabilities of this new infrastructure, the company simultaneously announced the advancement of six proprietary therapeutic programs, marking the successful expansion of XtalPi’s technology into nucleic acid therapeutics.

By silencing disease-driving genes upstream of protein production, siRNA therapeutics offer immense potential for biological targets that conventional modalities struggle to address. However, clinical development remains heavily constrained by fragmented sequence and modification design processes, restrictive patent barriers, inconsistent translation from cellular assays to animal models, and severe limitations in extrahepatic delivery.

To address these interdependent bottlenecks, XtalPi drew on domain-specific expertise to develop siFormer, the proprietary architecture at the core of Kodexia™. By seamlessly integrating RNAi biological mechanisms with nucleic acid chemistry principles, siFormer delivers a qualitative leap in predictive accuracy that surpasses conventional design baselines. The architecture incorporates RNA thermodynamics and structural features relevant to strand loading, target accessibility, and silencing efficiency. These mechanistic constraints guide molecular generation toward biologically plausible designs rather than relying on sequence correlations alone. Through this unified approach, Kodexia™ enables researchers to systematically balance potency, in vivo translation, durability, off-target activity, safety, and patentability instead of optimizing single endpoints in isolation.

To execute this multiparameter optimization, XtalPi utilizes a closed-loop process of computational design, automated experimentation, and empirical feedback. Generative models and the proprietary siFormer architecture operate continuously with XtalPi’s automated laboratories, which conduct more than 500 in vitro and 30 in vivo experiments weekly. This seamless integration enables the parallel development of multiple target programs, yielding a nearly threefold increase in design efficiency. Notably, more than 50% of first-round designs tested across multiple programs showed stronger in vivo activity than positive controls.

Kodexia™ also globally co-optimizes dual-target siRNAs as single molecules, creating a strategy for disease biology that may not be adequately addressed through single-target intervention. For extrahepatic delivery, the platform co-designs siRNA molecules with their targeting systems and applies multi-objective optimization to antibody, peptide, and small-molecule conjugates. These capabilities are being applied to delivery research targeting the kidney, spleen, and adipose tissue.

The platform’s lead program in immunoglobulin A (IgA) nephropathy serves as an early empirical validation of this unified architecture. The program reached non-human primate efficacy data within seven months, demonstrating greater activity and durability than a clinical-stage reference molecule targeting the same target. The program is on track for preclinical candidate selection within a nine-month project timeline, significantly accelerating the industry norm of 12 to 18 months.

Kodexia™ currently drives six proprietary programs across metabolic, renal, respiratory, and central nervous system diseases, with more than half having already completed in vivo efficacy evaluations. Each internal program generates high-value experimental data that feeds directly back into the platform’s models, reinforcing a continuous cycle of discovery and commercial translation. As a global scientific utility platform, XtalPi leverages this capability alongside its established expertise in small molecules, antibodies, and peptides. By advancing these internal assets in tandem with established industry collaborations, XtalPi empowers its partners to pursue high-value targets using the modality best suited to the mechanistic and biophysical principles of RNA interference, including RNA thermodynamics and structural features, ultimately accelerating the delivery of next-generation RNA therapies for patients worldwide.

About XtalPi

XtalPi Holdings Limited (XtalPi, 2228.HK) was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries.

Railtown AI Launches Native Swift Agent Development Technology for the Next Generation of Agentic Applications

New Railtracks for Swift ADK and Railengine Swift SDK bring native agent development, cross-device context, and accountability to Apple platforms as Railtown advances its vision for private, secure, and observable agentic software.

Vancouver, British Columbia – Newsfile Corp. – October 6, 2026 – Railtown AI Technologies Inc. (CSE: RAIL) (OTCQB: RLAIF) (“Railtown” or the “Company“) today announced the launch of a native Railtracks Agent Development Kit (ADK) for Swift and a new Swift SDK for Railengine, bringing Railtown’s agentic application infrastructure directly into the development ecosystem used to build applications across Apple platforms.

The launch reflects a broader conviction at Railtown: Apple’s ecosystem has the potential to become one of the defining platforms for the next generation of agentic software.

Software is beginning to move beyond applications that simply wait for users to tell them what to do. The next generation of applications will increasingly understand context, reason across information, use tools, collaborate with other agents and take actions on a user’s behalf.

That transition changes what developers need from a computing platform.

Agents need intelligence, but intelligence alone is not enough. They need context. They need to move with users across their digital lives while respecting privacy and security. And as agents become capable of taking increasingly consequential actions, users and enterprises need visibility and accountability into what those agents are doing.

Railtown believes Apple’s combination of devices, silicon, native development technologies, on-device intelligence, privacy architecture and tightly integrated ecosystem creates a compelling foundation for this emerging model of computing.

Railtown is building the agentic infrastructure around that foundation.

Building Agentic Applications Natively in Swift

Swift has become central to the native development experience across Apple platforms, including iPhone, iPad, Mac, Apple Watch and Apple Vision Pro.

Railtown’s new Railtracks ADK for Swift brings its agent development technology directly into that environment, giving Swift developers native building blocks for creating agentic applications, including agents, tools, orchestration, workflows and multi-agent systems.

Rather than treating AI as an external service simply connected to an application, Railtown believes agentic capabilities should increasingly become a native part of the application architecture itself.

Railtracks for Swift is designed to allow developers to combine agentic reasoning with the frameworks, models and capabilities available across Apple platforms, opening the door to a new generation of applications that can understand, reason and act within the environments where users already work, communicate and create.

From Individual Devices to Continuous Agentic Experiences

Railtown is also bringing Railengine to Swift through a new native SDK, providing developers with a contextual intelligence layer for agentic applications.

The future of personal agents will not be confined to a single application session or a single device.

A user may capture information on an iPhone, continue working on a Mac and later interact with an agent that needs to understand the context of both experiences. For an agent to become genuinely useful, it must be capable of retrieving the right context at the right moment without requiring users to repeatedly reconstruct that context themselves.

Railengine is designed to help make that possible.

Within Railtown’s architecture, personally identifiable information remains in the data layer and is retrieved from iCloud, allowing applications to access relevant context while preserving the separation between personal identity information and the intelligence systems using that context.

This creates the foundation for continuous agentic experiences across Apple devices designed around privacy from the beginning.

The result represents a fundamentally different approach to AI applications:

Intelligence that follows the user’s context rather than requiring the user’s data to follow the AI.

Intelligence Requires Accountability

As software gains agency, Railtown believes another principle becomes increasingly important:

The more autonomy software receives, the more accountable it must become.

Traditional software is largely deterministic. Agentic software can reason, select tools, generate responses, interact with other systems, and take actions.

That means developers increasingly need to understand not only whether an application failed, but what an agent did, which tools it used, how it behaved and why a particular outcome occurred.

Railtown is extending its observability technology into the Swift development lifecycle so developers can inspect agent executions, understand tool usage, evaluate behaviour, and diagnose failures as they build.

Railtown’s Conductr platform extends that accountability model into production through centralized agent observability, error analysis, and root cause analysis.

For enterprises, Railtown is also developing an architecture designed to provide visibility and governance across agentic applications from multiple developers while maintaining appropriate boundaries between enterprise information, individual privacy, and developer intellectual property.

Together, Railtown’s technology creates a continuous agentic software lifecycle:

Build → Understand → Deploy → Observe → Improve

Apple as a Platform for the Agentic Era

Railtown believes the emergence of agents represents more than another generation of applications. It has the potential to change the relationship between users, applications and the operating platforms connecting them.

Personal agents will need access to context across applications and devices.

Enterprise agents will need to operate within organizational security and governance boundaries.

Developers will need native frameworks and infrastructure for building them.

And users will need confidence that increasingly autonomous software remains private, secure, and understandable.

Railtown believes few technology ecosystems bring those requirements together as naturally as Apple’s.

Apple has spent decades building the hardware, operating systems, silicon, development frameworks, and privacy architecture used by developers to create applications that operate across an increasingly connected family of personal devices. Railtown believes that same foundation could enable an emerging generation of third-party agentic applications capable of moving with users across their digital lives.

“AI becomes much more powerful when it understands the context around us, but that cannot require giving up control of our personal information,” said Marwan Haddad, Co-Founder and CTO of Railtown AI. “Apple has spent years building an ecosystem around privacy, security, integrated devices, and native developer experiences. We believe those principles become even more important, not less important, as software becomes agentic.”

Railtown’s strategy is to provide the infrastructure developers need to build on that foundation:

Railtracks for Swift provides the agent development layer.

Railengine for Swift provides the contextual intelligence layer.

Railtown observability and Conductr provide the accountability layer.

Together, these technologies are designed to help developers build a new generation of personal and enterprise applications that can understand context, reason and act while remaining private, visible, and accountable.

“We believe some of the most important agentic applications of the next decade can be built across the Apple ecosystem,” added Haddad. “Our goal is to give developers the infrastructure to build them and to help ensure that as these applications become more capable, they also become more accountable.”

“We believe Apple’s ecosystem could become a major platform for agentic applications, creating a significant opportunity for developers and for Railtown,” said Cory Brandolini, CEO of Railtown AI. “But while customers often hear how quickly someone can build an AI agent, the question is whether that agent is ready to be trusted with their business. SMEs need applications built to rigorous standards for reliability, privacy, security and accountability-the trust we believe Apple’s App Store model has helped establish. Our strategy is to provide the infrastructure developers need to earn that trust, from building agents and connecting them to relevant context to understanding how they behave in production. Bringing Railtracks and Railengine to Swift is an important step toward that goal.”

About Railtown AI
Railtown AI Technologies Inc. develops infrastructure for building and operating AI agents and agentic applications. Railtown’s technology spans agent development through Railtracks, contextual intelligence through Railengine, and production observability and management through Conductr.

Railtown’s mission is to help developers and organizations build agentic software that is powerful, contextual, private, and accountable.

For more information, visit www.railtown.ai.

www.railtracks.org
www.railengine.ai
www.conductr.ai

Follow us on social media

SUBSCRIBE FOR INVESTOR NEWS
Click here to receive our latest investor news alerts.

ON BEHALF OF THE BOARD
“Cory Brandolini”
Cory Brandolini, Chief Executive Officer

INVESTOR CONTACT
Investor Relations Contact
Email: investors@railtown.ai
Phone: 1-778-918-8384

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will,” “may”, “should”, “intends”, “anticipates”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including, without limitation, statements regarding the future plans and objectives of the Company, the commencement of trading of the Company’s common shares on the CSE, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations are risks detailed from time to time in the filings made by the Company with securities regulators.

Readers are cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that any forward-looking statement will materialize, and readers should not place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will only update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

The issuer is solely responsible for the content of this announcement.

NANO Nuclear Energy Appoints Former Y-12 Leader and Nuclear Fuel Cycle Expert Jennifer Charlton, Ph.D., as Vice President of Fuel Technology to Accelerate Vertical Integration Strategy

New York, New York – Newsfile Corp. – October 6, 2026 – NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear micro modular reactor and technology company focused on developing clean energy solutions, nuclear fuel cycle capabilities and nuclear transportation solutions, today announced that it has hired Jennifer Charlton, Ph.D., as its Vice President of Fuel Technology.

Dr. Charlton brings nearly two decades of experience in nuclear materials, uranium processing, fuel-cycle technology, and advanced manufacturing to NANO Nuclear. Prior to joining NANO Nuclear, Dr. Charlton held several senior technical and leadership positions at the Y-12 National Security Complex. Notably, she served as Chief Scientist and U.S. Lead for Nuclear Material Verification, leading technical initiatives and providing comprehensive technical expertise across the nuclear fuel cycle, from uranium mining and milling through conversion, enrichment, fuel fabrication, and finished fuel and weapons component operations.

“NANO Nuclear’s strategic focus on building capabilities across key areas of the nuclear fuel cycle is an important part of supporting its long-term microreactor deployment strategy,” said Jennifer Charlton, Ph.D., Vice President of Fuel Technology of NANO Nuclear Energy. “I’m excited to join the team at this important stage of its growth and leverage my experience leading complex technical initiatives to help advance this strategy and strengthen NANO Nuclear’s capabilities across the fuel cycle.”

Figure 1 – NANO Nuclear Energy Hires Former Y-12 Leader and Nuclear Fuel Cycle Expert, Jennifer Charlton Ph.D. as its Vice President of Fuel Technology.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/11703/317616_08bb19ec343c59a3_002full.jpg

Dr. Charlton earned a Ph.D. in Chemistry from the University of Tennessee, a Bachelor of Science in Chemistry from the University of North Florida, and an Associate of Arts from Florida State College. Her graduate research encompassed automated radiochemical separations, nanofabrication, surface-enhanced spectroscopy, mass spectrometry, instrumentation development, nuclear forensics, trace-level materials analysis, and materials characterization.

“It is a pleasure to welcome Dr. Charlton to the NANO Nuclear team,” said Jay Yu, Founder and Chairman of NANO Nuclear Energy. “Her addition marks another step towards ensuring that we have the right personnel to oversee NANO Nuclear’s long-term strategic focus on vertical integration. Her experience within the Y-12 National Security Complex will be invaluable as we look to expand our capabilities across the nuclear fuel cycle.”

Dr. Charlton joins a growing list of former senior nuclear leaders and builds on NANO Nuclear’s recently announced addition of Marylin Diaz to support the Company’s expansion across the nuclear fuel cycle. In her role as Vice President of Fuel Technology, Dr. Charlton will be responsible for evaluating opportunities to expand NANO Nuclear’s capabilities across the nuclear fuel cycle and leading the design, engineering, and development of related technologies, with a focus on the uranium conversion, deconversion, and fuel fabrication processes. She will also provide technical expertise to inform strategic decisions regarding NANO Nuclear’s broader vertical integration strategy in support of future advanced reactor deployments and nuclear logistics activities.

“As our core, proprietary technology, the KRONOS MMR™ Energy System, continues along its development pathway, we are working to expand across the nuclear fuel cycle to help de-risk the marketplace as well as support the energy sovereignty of the United States,” said James Walker, Chief Executive Officer of NANO Nuclear Energy. “Dr. Charlton’s appointment is a key step in that effort, and I am delighted to welcome her to the Company. I believe that Dr. Charlton’s addition, as well as her experience and knowledge of the inner workings of the fuel cycle will prove to be incredibly important as we continue to put together the building blocks for our next stages of growth.”

About NANO Nuclear Energy, Inc.
NANO Nuclear Energy Inc. (NASDAQ: NNE) is a North American advanced technology-driven nuclear energy company seeking to become a commercially focused, diversified, and vertically integrated company across five business lines: (i) cutting edge portable and other microreactor technologies, (ii) nuclear fuel supply chain, (iii) nuclear fuel transportation, (iv) nuclear applications for space and (v) nuclear industry consulting services.

Led by a world-class nuclear engineering team, NANO Nuclear’s reactor products in development include the proprietary KRONOS MMR™ Energy System, a stationary high-temperature gas-cooled reactor that is in construction permit pre-application engagement U.S. Nuclear Regulatory Commission (NRC) in collaboration with University of Illinois Urbana-Champaign, the ZEUS™ system, a portable solid core battery reactor, and the space focused, portable LOKI MMR™ system, each representing advanced developments in clean energy solutions that are portable, on-demand capable, advanced nuclear microreactors.

Advanced Fuel Transportation Inc. (AFT), a NANO Nuclear subsidiary, bolstered by the May 2026 acquisition of Secured Transportation Services (STS), is led by former executives from the largest transportation company in the world and provides nuclear engineering and materials transport services in the U.S. and globally. Through NANO Nuclear, AFT is the exclusive licensee of a patented high-capacity HALEU fuel transportation basket developed by three major U.S. national nuclear laboratories and funded by the Department of Energy.

HALEU Energy Fuel Inc. (HEF), a NANO Nuclear subsidiary, is focusing on the future development of a domestic source for a High-Assay, Low-Enriched Uranium (HALEU) fuel fabrication pipeline for NANO Nuclear’s own microreactors as well as the broader advanced nuclear reactor industry.

NANO Nuclear Space Inc. (NNS), a NANO Nuclear subsidiary, is exploring the potential commercial applications of NANO Nuclear’s developing micronuclear reactor technology in space. NNS is focusing on applications such as the LOKI MMR™ system and other power systems for extraterrestrial projects and human sustaining environments, and potentially propulsion technology for long haul space missions. NNS’ initial focus will be on cis-lunar applications, referring to uses in the space region extending from Earth to the area surrounding the Moon’s surface.

For more corporate information please visit: https://NanoNuclearEnergy.com/

For further NANO Nuclear information, please contact:
Email: IR@NANONuclearEnergy.com
Business Tel: (212) 634-9206

PLEASE FOLLOW OUR SOCIAL MEDIA PAGES HERE:
NANO Nuclear Energy LINKEDIN
NANO Nuclear Energy YOUTUBE
NANO Nuclear Energy X PLATFORM

Cautionary Note Regarding Forward Looking Statements
This news release and statements of NANO Nuclear’s management and collaborators in connection with this news release contain or may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as “expects”, “anticipates”, “intends”, “explore,” “plans”, “aim,” “goal,” “believes”, “potential”, “future,” “will”, “should”, “could”, “would” or “may” or derivations of these words and other words of similar meaning about the future, although forward-looking statements could be denoted by other terms as well. In this press release, forward-looking statements relate to the anticipated benefits of Dr. Charlton joining the Company, as well as the Company’s vertical integration and other operational plans and goals. These and other forward-looking statements are based on information available to us as of the date of this news release and represent management’s current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors, which may be beyond our control. For NANO Nuclear, particular risks and uncertainties that could cause our actual future results to differ materially from those expressed in our forward-looking statements include but are not limited to, risks associated with conditions to closing the asset purchase agreement, which may not be satisfied, including for reasons beyond NANO Nuclear’s control, as well as the following: (i) risks related to our U.S. Department of Energy (“DOE”), U.S. Nuclear Regulatory Commission (“NRC”), Canadian Nuclear Safety Commission (“CNSC”) or related state or other U.S. or non-U.S nuclear licensing submissions, (ii) risks related the development of new or advanced technology and the acquisition of complementary technology or businesses, including difficulties with design and testing, cost overruns, regulatory delays, integration issues and the development of competitive technology, (iii) risks related to our ability to obtain key vendor, technology and customer contracts and the significant funding necessary to execute on our business plan, (iv) risks related to uncertainty regarding our ability to technologically develop and commercially deploy a competitive advanced nuclear reactor or other technology in the timelines we anticipate, if ever, (v) risks related to the impact of U.S. and non-U.S. government regulation, policies and licensing requirements, including by the U.S. Department of Energy, and the NRC, including those associated with the recently enacted ADVANCE Act and the May 23, 2025 Executive Orders seeking to streamline nuclear regulation, and (vi) similar risks and uncertainties associated with the operating a developing business a highly regulated, competitive and rapidly evolving industry, including that our plans may change and we may use our cash on hand faster or in different ways than anticipated as our business requires. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. These factors may not constitute all factors that could cause actual results to differ from those discussed in any forward-looking statement, and NANO Nuclear therefore encourages investors to review other factors that may affect future results in its filings with the SEC, which are available for review at www.sec.gov and at https://ir.nanonuclearenergy.com/financial-information/sec-filings. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.

The issuer is solely responsible for the content of this announcement.